Clinical data on the relationships of cytochrome P450 (CYP2) B6 516G> T polymorphisms
with efavirenz-induced central nervous system (CNS) side effects and virological response …

Objectives Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have
been associated with high interindividual variation in efavirenz pharmacokinetics. However …

The purpose of this study was to investigate the impact of CYP2B6‐G516T polymorphisms
on the pharmacokinetics (PKs) of efavirenz among the Chinese population and to propose …

Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side
effects occur commonly, and population (racial) differences in pharmacokinetics and …

Abstract In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized
relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma …

The aim of this study was to assess the influence of host genetic variations and clinical
factors in relation to efavirenz level in HIV-1 infected Thai adults. A total of 100 HIV-infected …

Background Human immunodeficiency virus type 1 (HIV-1) infections with a plasma
efavirenz concentration of< 1,000 ng/mL appear to have a high risk for the emergence of …

Objective We aimed at comparing clinical/immunological outcomes in human
immunodeficiency virus (HIV)-infected patients who were treated with CYP2B6-guided and …

Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the
treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well …

Objective: UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main
enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether …